Atopic Dermatitis (Eczema)

Atopic Dermatitis

(Eczema) Trial

Phase 2 | Injection | 16 week treatment period | 16 week safety follow up

• ≥ 18 years old
• Moderate to Severe Eczema, for at least 1 year
• Eczema must cover more than 10% of the body
• Condition must not have improved after use of creams/other treatments for at least one month

Trial ID: NCT06015308

Exclusion Criteria:

• Received a pneumococcal vaccine, or more than two doses of the vaccine in the last 5 years
• Received a vaccine for tetanus, diphtheria, or pertussis (whooping cough) in the last 5 years

Atopic Dermatitis

(Eczema) Trial

Trial ID: NCT05995964

Phase 2 | Injection | 12 week treatment period

• ≥ 18 years old
• Moderate to Severe Eczema for ≥ 6 months
• Eczema must cover more than 10% of the body
• Condition has not improved, and have not used a topical corticosteroid or topical calcineurin inhibitor for at least one month

Exclusion Criteria:

• Smoke more than 10 cigarettes a day
• Heavily smoked for many years

Atopic Dermatitis

(Eczema) Trial

Trial ID: NCT06241118

Phase 3 | Injection | 36 week treatment period | 16 week safety follow up

• ≥ 12 years old
• Moderate to Severe Eczema for at least 1 year
• Condition has not improved after using at least one biologic Eczema medication for a minimum 4 months, or one oral JAK inhibitor for at least 2 months, or if unable to tolerate those treatments
• Must agree to use a moisturizing cream (emollient) regularly

Exclusion Criteria:

• Body weight under 25 kg
• History of solid organ or stem cell transplant

Atopic Dermatitis

(Eczema) Trial

Phase 3 | Injection | 52 week treatment period

Trial ID: NCT06224192

• ≥ 12 years old
• Moderate to Severe Eczema with a history of the condition of ≥ 12 months
• Must have had an inadequate response, intolerance, or contraindication to a topical corticosteroid applied for > 1 month

Exclusion Criteria:

• Previous exposure to anti-OC40/40L therapies
• A washout period is required for those previously treated with biologics or JAK inhibitors

Atopic Dermatitis

(Eczema) Trial

Phase 3 | Injection | 52 week treatment period

Trial ID: NCT05633355

Atopic Dermatitis

(Eczema) Trial

Trial ID: NCT05398445

Phase 3 | Injection | 24 week treatment period